Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diet, Protein-Restricted | 9 | 2024 | 81 | 3.870 |
Why?
|
| Insulin Resistance | 9 | 2022 | 643 | 3.330 |
Why?
|
| Polycystic Ovary Syndrome | 4 | 2022 | 58 | 2.820 |
Why?
|
| Glucose Intolerance | 5 | 2022 | 78 | 2.570 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2024 | 229 | 1.830 |
Why?
|
| Reproduction | 2 | 2025 | 239 | 1.560 |
Why?
|
| Phenols | 3 | 2025 | 55 | 1.500 |
Why?
|
| Endocrine Disruptors | 2 | 2025 | 52 | 1.380 |
Why?
|
| Benzhydryl Compounds | 2 | 2025 | 65 | 1.370 |
Why?
|
| Glucose | 5 | 2023 | 885 | 1.040 |
Why?
|
| Muscle, Skeletal | 5 | 2024 | 951 | 0.940 |
Why?
|
| Hyperandrogenism | 3 | 2022 | 19 | 0.920 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 1244 | 0.850 |
Why?
|
| Ovary | 3 | 2021 | 380 | 0.830 |
Why?
|
| Rats | 15 | 2024 | 3686 | 0.810 |
Why?
|
| Androgens | 3 | 2022 | 275 | 0.800 |
Why?
|
| Rats, Wistar | 6 | 2024 | 360 | 0.770 |
Why?
|
| Endocrinology | 1 | 2023 | 136 | 0.730 |
Why?
|
| Paternal Age | 1 | 2020 | 13 | 0.700 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2017 | 48 | 0.680 |
Why?
|
| Fathers | 1 | 2020 | 68 | 0.660 |
Why?
|
| Fetal Development | 1 | 2021 | 131 | 0.650 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 69 | 0.630 |
Why?
|
| Folic Acid | 2 | 2019 | 292 | 0.620 |
Why?
|
| Oocytes | 4 | 2022 | 284 | 0.610 |
Why?
|
| Vitamin B Complex | 2 | 2019 | 41 | 0.610 |
Why?
|
| Pregnancy | 17 | 2024 | 7167 | 0.600 |
Why?
|
| Insulin | 3 | 2022 | 1207 | 0.600 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2017 | 78 | 0.580 |
Why?
|
| Testosterone | 4 | 2020 | 534 | 0.550 |
Why?
|
| Animals | 23 | 2025 | 34145 | 0.550 |
Why?
|
| Thinness | 1 | 2016 | 69 | 0.500 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2824 | 0.490 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2015 | 18 | 0.490 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 17 | 0.480 |
Why?
|
| Estradiol | 2 | 2020 | 534 | 0.470 |
Why?
|
| Signal Transduction | 4 | 2017 | 4535 | 0.470 |
Why?
|
| Insulin-Secreting Cells | 2 | 2015 | 150 | 0.460 |
Why?
|
| Benzopyrans | 3 | 2013 | 19 | 0.450 |
Why?
|
| Female | 27 | 2025 | 66235 | 0.450 |
Why?
|
| Mitochondria | 5 | 2023 | 689 | 0.450 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 414 | 0.450 |
Why?
|
| Receptors, Estrogen | 3 | 2013 | 794 | 0.440 |
Why?
|
| Maternal Exposure | 1 | 2015 | 148 | 0.440 |
Why?
|
| Receptors, Prostaglandin | 2 | 2013 | 22 | 0.420 |
Why?
|
| Glucose Tolerance Test | 3 | 2020 | 209 | 0.410 |
Why?
|
| Estrogen Receptor beta | 4 | 2013 | 79 | 0.390 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2012 | 10 | 0.390 |
Why?
|
| Blood Glucose | 2 | 2015 | 1129 | 0.380 |
Why?
|
| Progesterone | 2 | 2012 | 625 | 0.330 |
Why?
|
| Neutrophils | 1 | 2012 | 378 | 0.330 |
Why?
|
| Estrogen Receptor alpha | 4 | 2013 | 468 | 0.310 |
Why?
|
| Adrenomedullin | 2 | 2023 | 74 | 0.310 |
Why?
|
| DNA, Mitochondrial | 3 | 2024 | 211 | 0.260 |
Why?
|
| Stilbenes | 1 | 2006 | 36 | 0.260 |
Why?
|
| Mitochondrial Dynamics | 2 | 2024 | 46 | 0.260 |
Why?
|
| Estrogen Antagonists | 1 | 2006 | 103 | 0.260 |
Why?
|
| Hypertension | 1 | 2014 | 1282 | 0.260 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 483 | 0.250 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1228 | 0.250 |
Why?
|
| Fluorocarbons | 1 | 2025 | 56 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 488 | 0.230 |
Why?
|
| Estrogens | 1 | 2006 | 515 | 0.220 |
Why?
|
| Embryonic Development | 1 | 2025 | 210 | 0.210 |
Why?
|
| Sex Factors | 2 | 2017 | 1267 | 0.210 |
Why?
|
| Labor, Induced | 2 | 2013 | 34 | 0.190 |
Why?
|
| Cervix Uteri | 2 | 2013 | 63 | 0.190 |
Why?
|
| Diabetes, Gestational | 1 | 2023 | 112 | 0.190 |
Why?
|
| Uterus | 4 | 2012 | 571 | 0.190 |
Why?
|
| Sex Differentiation | 1 | 2021 | 20 | 0.180 |
Why?
|
| Male | 9 | 2025 | 60962 | 0.180 |
Why?
|
| Single-Cell Analysis | 1 | 2023 | 275 | 0.180 |
Why?
|
| Mice, Obese | 1 | 2020 | 78 | 0.180 |
Why?
|
| Fasting | 1 | 2022 | 300 | 0.170 |
Why?
|
| Humans | 13 | 2025 | 124299 | 0.170 |
Why?
|
| Adenosine Triphosphate | 1 | 2020 | 284 | 0.170 |
Why?
|
| Infertility, Female | 1 | 2021 | 145 | 0.170 |
Why?
|
| Aneuploidy | 1 | 2020 | 154 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2024 | 777 | 0.160 |
Why?
|
| Ovariectomy | 2 | 2012 | 182 | 0.160 |
Why?
|
| Obesity | 2 | 2020 | 2250 | 0.160 |
Why?
|
| Testis | 1 | 2020 | 411 | 0.150 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 67 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2017 | 64 | 0.140 |
Why?
|
| Overweight | 1 | 2020 | 360 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2014 | 87 | 0.130 |
Why?
|
| Amino Acids | 1 | 2019 | 663 | 0.130 |
Why?
|
| Testosterone Propionate | 1 | 2015 | 3 | 0.130 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 29 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2022 | 1547 | 0.130 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 68 | 0.120 |
Why?
|
| Mice | 3 | 2022 | 17727 | 0.120 |
Why?
|
| Flutamide | 1 | 2014 | 26 | 0.120 |
Why?
|
| Estrous Cycle | 1 | 2014 | 35 | 0.120 |
Why?
|
| Mesenteric Arteries | 1 | 2014 | 57 | 0.120 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2014 | 20 | 0.110 |
Why?
|
| Vasoconstriction | 1 | 2014 | 102 | 0.110 |
Why?
|
| Pregnancy, Prolonged | 1 | 2013 | 3 | 0.110 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 6 | 0.110 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 4 | 0.110 |
Why?
|
| Cervical Ripening | 1 | 2013 | 7 | 0.110 |
Why?
|
| Uterine Artery | 1 | 2014 | 29 | 0.110 |
Why?
|
| Ovulation | 1 | 2014 | 109 | 0.110 |
Why?
|
| Receptors, Progesterone | 2 | 2009 | 879 | 0.110 |
Why?
|
| Neuropeptides | 1 | 2014 | 114 | 0.110 |
Why?
|
| Models, Animal | 1 | 2016 | 465 | 0.110 |
Why?
|
| GTPase-Activating Proteins | 1 | 2014 | 85 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 54 | 0.110 |
Why?
|
| Angiotensin II | 1 | 2014 | 162 | 0.110 |
Why?
|
| Vasodilation | 1 | 2014 | 189 | 0.110 |
Why?
|
| Phosphorylation | 1 | 2017 | 1625 | 0.100 |
Why?
|
| Oxygen Consumption | 2 | 2024 | 306 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 507 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2016 | 470 | 0.100 |
Why?
|
| HL-60 Cells | 1 | 2012 | 32 | 0.100 |
Why?
|
| Pertussis Toxin | 1 | 2012 | 24 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2014 | 1322 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2012 | 701 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 62 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2013 | 284 | 0.100 |
Why?
|
| Piperidines | 1 | 2013 | 204 | 0.100 |
Why?
|
| Weight Gain | 1 | 2014 | 404 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 515 | 0.090 |
Why?
|
| Nitriles | 1 | 2012 | 146 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 2801 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 368 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1685 | 0.090 |
Why?
|
| Ligands | 1 | 2012 | 536 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 887 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 292 | 0.080 |
Why?
|
| Embryo Implantation | 2 | 2008 | 234 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2009 | 77 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2012 | 307 | 0.080 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2008 | 17 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 3052 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1015 | 0.080 |
Why?
|
| Endometrium | 2 | 2008 | 282 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 2535 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 530 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 60 | 0.070 |
Why?
|
| Response Elements | 1 | 2006 | 97 | 0.070 |
Why?
|
| COS Cells | 1 | 2006 | 276 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2006 | 290 | 0.060 |
Why?
|
| Mitochondria, Muscle | 1 | 2024 | 35 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3578 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4355 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2008 | 911 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12288 | 0.050 |
Why?
|
| Cytochromes b | 1 | 2023 | 5 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 237 | 0.050 |
Why?
|
| Adipocytes | 1 | 2023 | 159 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 1684 | 0.050 |
Why?
|
| Gene Expression | 2 | 2019 | 1569 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2023 | 229 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2505 | 0.050 |
Why?
|
| Lipids | 1 | 2023 | 512 | 0.040 |
Why?
|
| Follicular Phase | 1 | 2019 | 15 | 0.040 |
Why?
|
| Cumulus Cells | 1 | 2019 | 43 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 121 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 1288 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1321 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2015 | 49 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2008 | 1108 | 0.030 |
Why?
|
| C-Peptide | 1 | 2015 | 113 | 0.030 |
Why?
|
| Corpus Luteum | 1 | 2014 | 25 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 174 | 0.030 |
Why?
|
| Pancreas | 1 | 2015 | 217 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2014 | 46 | 0.030 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Calgranulin B | 1 | 2013 | 10 | 0.030 |
Why?
|
| Furin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Acetylcholine | 1 | 2014 | 83 | 0.030 |
Why?
|
| Peptide Hormones | 1 | 2014 | 68 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2013 | 19 | 0.030 |
Why?
|
| Granulosa Cells | 1 | 2014 | 133 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2013 | 6 | 0.030 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2013 | 5 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2013 | 184 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 112 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 106 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 222 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 122 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1017 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 1003 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 340 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1341 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3268 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1787 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2304 | 0.020 |
Why?
|
| Epithelium | 1 | 2007 | 361 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1459 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1658 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 6075 | 0.010 |
Why?
|
| Adult | 2 | 2013 | 29386 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 8976 | 0.010 |
Why?
|